×
About 7,837 results

ALLMedicine™ Hemophilia A Center

Research & Reviews  3,435 results

Thrombin generation potential in the presence of concizumab and rFVIIa, aPCC, rFVIII or...
https://doi.org/10.1111/jth.15323
Journal of Thrombosis and Haemostasis : JTH; Kjalke M, Kjelgaard-Hansen M et. al.

Apr 5th, 2021 - The anti-TFPI monoclonal antibody concizumab is under clinical investigation for subcutaneous prophylaxis of hemophilia A/B (HA/HB) with or without inhibitors. Breakthrough bleeds while on concizumab prophylaxis may be treated with bypassing agent...

Genetic analysis of carrier status in female members of Japanese hemophilia families.
https://doi.org/10.1111/jth.15301
Journal of Thrombosis and Haemostasis : JTH; Shinozawa K, Amano K et. al.

Mar 24th, 2021 - Genetic characteristics and genetic carrier diagnosis in Japanese hemophilia female carriers have not been evaluated. To provide genetic information on Japanese hemophilia female carriers and demonstrate the advantages of genetic testing in carrie...

Population Pharmacokinetic Analysis of Recombinant Factor VIII Fc Fusion Protein in Sub...
https://doi.org/10.1002/jcph.1854
Journal of Clinical Pharmacology; Katragadda S, Neelakantan S et. al.

Mar 15th, 2021 - Recombinant factor VIII Fc fusion protein (rFVIIIFc) has been indicated for adults and children with hemophilia A. The objective of this manuscript is to build a population pharmacokinetic (PK) model using adult and pediatric datasets and explore ...

The spectrum of FVIII gene variants detected by next generation sequencing in 236 Chine...
https://doi.org/10.1016/j.thromres.2021.02.027
Thrombosis Research; Chen J, Li Q et. al.

Mar 11th, 2021 - The reported variants of hemophilia A are mainly from European subjects and American subjects of European descent, and limited data are available from more diverse ethnic backgrounds. This study was performed to identify the causative variants in ...

see more →

Guidelines  15 results

Current practices in hemophilic patients undergoing orthopedic surgery - a systematic review
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7588779/
Experimental and Therapeutic Medicine; Badulescu OV

Oct 13th, 2020 - Hemophilia is an inherited disease that requires a different approach in order to evaluate, monitor and treat patients. Despite the great advances in therapeutic agents that have emerged, reports on the impact of monitoring outcomes on treatment d...

Bayer Statement on Voluntary Recall of Two Lots of Kogenate FS Antihemophilic Factor (Recombinant) in the United States
https://www.drugs.com/fda/bayer-statement-voluntary-recall-two-lots-kogenate-fs-antihemophilic-factor-recombinant-united-14291.html

Jul 18th, 2019 - Bayer is voluntarily recalling two lots of Kogenate FS antihemophilic factor (recombinant) 2000 IU vials in the United States to the patient level. Certain vials from these two lots that were labeled as Kogenate FS actually contain the FVIII hemop...

Novo Nordisk receives US FDA approval of ESPEROCT® (turoctocog alfa pegol, N8-GP)
https://www.novonordisk.com/content/Denmark/HQ/www-novonordisk-com/en_gb/home/media/news-details.2235689.html

Feb 18th, 2019 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application for ESPEROCT® for the treatment of adults and children with haemophilia A. ESPEROCT® is the brand name for turoctocog alfa p...

NHF-McMaster Guideline on Care Models for Haemophilia Management
https://onlinelibrary.wiley.com/doi/abs/10.1111/hae.13008
Pai, M.

Jun 26th, 2016 - This guideline was developed to identify evidence?based best practices in haemophilia care delivery, and discuss the range of care providers and services that are most important to optimize outcomes for persons with haemophilia (PWH) across the Un.

International recommendations on the diagnosis and treatment of patients with acquired ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663620
Haematologica Huth-Kühne A, Baudo F et. al.

Apr 1st, 2009 - Acquired hemophilia A (AHA) is a rare bleeding disorder characterized by autoantibodies directed against circulating coagulation factor (F) VIII. Typically, patients with no prior history of a bleeding disorder present with spontaneous bleeding an...

see more →

Drugs  109 results see all →

Clinicaltrials.gov  3,717 results

Thrombin generation potential in the presence of concizumab and rFVIIa, aPCC, rFVIII or...
https://doi.org/10.1111/jth.15323
Journal of Thrombosis and Haemostasis : JTH; Kjalke M, Kjelgaard-Hansen M et. al.

Apr 5th, 2021 - The anti-TFPI monoclonal antibody concizumab is under clinical investigation for subcutaneous prophylaxis of hemophilia A/B (HA/HB) with or without inhibitors. Breakthrough bleeds while on concizumab prophylaxis may be treated with bypassing agent...

Genetic analysis of carrier status in female members of Japanese hemophilia families.
https://doi.org/10.1111/jth.15301
Journal of Thrombosis and Haemostasis : JTH; Shinozawa K, Amano K et. al.

Mar 24th, 2021 - Genetic characteristics and genetic carrier diagnosis in Japanese hemophilia female carriers have not been evaluated. To provide genetic information on Japanese hemophilia female carriers and demonstrate the advantages of genetic testing in carrie...

Advate - antihemophilic factor (recombinant) kit-Baxalta US Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80fa03d2-cd4c-4155-9b57-1396c4fa42da

Mar 17th, 2021 - ADVATE [Antihemophilic Factor (Recombinant)] is a recombinant antihemophilic factor indicated for use in children and adults with hemophilia A (congenital factor VIII deficiency) for: Control and prevention of bleeding episodes. Perioperative mana...

Population Pharmacokinetic Analysis of Recombinant Factor VIII Fc Fusion Protein in Sub...
https://doi.org/10.1002/jcph.1854
Journal of Clinical Pharmacology; Katragadda S, Neelakantan S et. al.

Mar 15th, 2021 - Recombinant factor VIII Fc fusion protein (rFVIIIFc) has been indicated for adults and children with hemophilia A. The objective of this manuscript is to build a population pharmacokinetic (PK) model using adult and pediatric datasets and explore ...

see more →

News  561 results

Fast Five Quiz: Presentation and Diagnosis of Hemophilia A
https://reference.medscape.com/viewarticle/939102_2

Oct 21st, 2020 - Hemophilia A is an inherited deficiency of FVIII and an X-linked recessive disorder. Hemophilia B, another recessive disorder, is characterized by a deficiency in factor IX. Hemophilia C is an autosomal recessive disorder in which patients are def...

Fast Five Quiz: Presentation and Diagnosis of Hemophilia A
https://reference.medscape.com/viewarticle/939102_4

Oct 21st, 2020 - Figure 2. Frontal x-ray showing the damaged knees of a patient with hemophilia. A fracture (lower left) in the right tibia has healed. Hemophilia is often associated with external bleeding, but a more common symptom is internal bleeding, which usu...

Fast Five Quiz: Presentation and Diagnosis of Hemophilia A
https://reference.medscape.com/viewarticle/939102

Oct 21st, 2020 - Hemophilia is a blood disorder that is usually genetically inherited from a parent, except for rare cases in which it is acquired. Hemophilia A is the most common type of hemophilia, and it is estimated to affect more than 1.2 million males worldw...

Current practices in hemophilic patients undergoing orthopedic surgery - a systematic review
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7588779/
Experimental and Therapeutic Medicine; Badulescu OV

Oct 13th, 2020 - Hemophilia is an inherited disease that requires a different approach in order to evaluate, monitor and treat patients. Despite the great advances in therapeutic agents that have emerged, reports on the impact of monitoring outcomes on treatment d...

FDA Declines to Approve BioMarin's Gene Therapy for Hemophilia A
https://www.staging.medscape.com/viewarticle/935960

Aug 19th, 2020 - (Reuters) - The U.S. Food and Drug Administration has declined to approve BioMarin Pharmaceutical Inc's gene therapy for hemophilia A, citing the need for two-year data on the therapy, the drugmaker said on Wednesday. The company, and Wall Street,...

see more →